Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (48)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Andrieu, J. M.
Right arrow Articles by Taillan, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andrieu, J. M.
Right arrow Articles by Taillan, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 4:635-641, 1993
© 1993 European Society for Medical Oncology

research-article

Hodgkin's disease during HIV1 infection: The French Registry Experience

J. M. Andrieu1,, S. Roithmann1, J. M. Tourani1, R. Levy1, B. Desablens2, C. le Maignan1, J. A. Gastaut3, P. Brice4, M. Raphael5 and B. Taillan6

1Hematology-Oncology Unit, Laennec Hospital Paris
2Hematology, Hôpital Sud Amiens
3Hematology, Institut Paoli Calmette Marseille
4Hematology, Hôpital Saint Louis
5Hematology, Hôpital de la Salpetriere Paris
6Hematology, Hôpital Cimiez Nice, France

Correspondence to: Prof. Jean-Marie Andrieu, Hematology/Oncology Unit, Laennec Hospital, 42 rue de Sevres, F - 75007 Paris, France

Background: The first cases of Hodgkin's disease (HD) associated with HIV infection were reported in 1984. Since then, short series of seropositive patients suffering from HD have been published. In order to identify the characteristics, treatment response and outcome of HIV-associated Hodgkin's disease (HIV-HD), the data of HIV-HD patients recorded between 1987 and 1989 were analysed and compared with those of primary HD patient and with those of HIV-associated non-Hodgkin's lymphoma (HIV-NHL), registered during the same period.

Patients and methods: The 45 cases of HD collected by the French registry of HIV-associated tumors between January 1987 and December 1989 were included in this study. All patients were clinically staged according to the Ann Arbor system. To compare HIV-HD characteristics with those of primary HD, we used a cohort of 407 patients with clinical stages (CS) LA to IVB, who were enrolled between September 1981 and August 1988 in a multicentric clinical trial. To identify the relationship between HIV-HD and the course of HIV infection we studied, when available, the routes of infection, initial CD4 cell count at the moment of HD diagnostic as well as the CDC class of HIV infection and compared these data with the same parameters observed in 142 HIV-NHL enrolled in the registry during the same period.

Results: HIV-HD is characterized by an increase in mixed-cellularity histology (49%), with a predominance of advanced stages (75%) and B symptoms (80%). A unique observation is made regarding mediastinal involvement, pesent in only 13% of HIV-HD (71% in primary HD). The HIV-HD/HIV-NHL ratio was significantly higher in intravenous drug abusers than in male homosexuals. Median CD4 cell count was 306/µl at HIV-HD diagnosis, and only 11% of the cases were preceded by an AIDS manifestation. With standard therapy, 79% of the patients achieved complete remission, but hematological and infectious complications were very frequent. The progression to AIDS rate was 94% at two years and opportunistic infections were the most frequent cause of death. Overall two-year survival was 41% with 71% for patients with initial CD 4 cell counts higher than 300/µl and 0% for those with CD4 cell counts lower than 300/µl (P ± 0.01).

Conclusion: HIV-HD has a particular clinico-pathological profile when compared to primary HD, with a predominance of mixed-cellularity type, a high frequency of advanced stages and a high proportion of patients without mediastinal involvement. Moreover, HIV-HD seems to occur preferentially in the group of subjects infected by needle sharing. Standard HD therapy seems to be efficient but excessively toxic.

chemotherapy, HIV infection, Hodgkin's disease, radiotherapy, survival


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 haematolHome page
B. Xicoy, J.-M. Ribera, P. Miralles, J. Berenguer, R. Rubio, B. Mahillo, M.-E. Valencia, E. Abella, A. Lopez-Guillermo, A. Sureda, et al.
Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma
Haematologica, February 1, 2007; 92(2): 191 - 198.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Hentrich, L. Maretta, K. U. Chow, J. R. Bogner, D. Schurmann, P. Neuhoff, H. Jager, D. Reichelt, M. Vogel, M. Ruhnke, et al.
Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study
Ann. Onc., June 1, 2006; 17(6): 914 - 919.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. M. Ansell and J. O. Armitage
Management of Hodgkin Lymphoma
Mayo Clin. Proc., March 1, 2006; 81(3): 419 - 426.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Hartmann, U. Rehwald, B. Salzberger, C. Franzen, M. Sieber, A. Wohrmann, and V. Diehl
BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection
Ann. Onc., October 1, 2003; 14(10): 1562 - 1569.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Spina, J. Gabarre, G. Rossi, M. Fasan, C. Schiantarelli, E. Nigra, M. Mena, A. Antinori, A. Ammassari, R. Talamini, et al.
Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection
Blood, August 28, 2002; 100(6): 1984 - 1988.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
A. M. Levine
Hodgkin's Disease in the Setting of Human Immunodeficiency Virus Infection
J Natl Cancer Inst Monographs, April 1, 1998; 1998(23): 37 - 42.
[Abstract] [Full Text]

Home page
 NEJMHome page
K. B. Knopf, G. Y. Locker, V. Diehl, and H. Tesch
Hodgkin's Disease and HIV Infection
N. Engl. J. Med., July 6, 1995; 333(1): 65 - 66.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.